Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect
NCT05816122 · View on ClinicalTrials.gov ↗
Study Summary
The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS). The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution. A secondary objective is to determine MSCopilot® Detect's ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients. Exploratory objectives include evaluating the relationship between MSCopilot® Detect composite and individual scores and other biomarkers such as MRI, soluble glial fibrillary acidic protein (sGFAP), and soluble neurofilament light chain (sNfL). Patients will be able to download the free MSCopilot® Detect app. They will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). Every 3 months, patients will complete validated questionnaires regarding MS symptoms and quality of life and participate in digital tests designed to monitor MS symptom progression. The study will include 336 MS patients and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France
Conditions Studied
Interventions
- DEVICE MSCopilot® Detect mobile application
Study Locations (20)
Other
- Galina Vorobeychik — Burnaby
- Mark Freedman — Ottawa
- St. Michael's Hospital — Toronto
- Robert Carruthers — Vancouver
- University Hospital of Southern Denmark — Esbjerg
- Finn Sellebjerg — Glostrup Municipality
- Sivagini Prakash — Viborg
- Hôpital Roger Salengro — Lille
- Cécile Donzé — Lomme
- Adil Maarouf — Marseille
California
- Jennifer Graves — San Diego
Georgia
- Joash Lazarus Sr. — Atlanta
Illinois
- Daniel Wynn — Northbrook
Indiana
- Craig E. Herrman — Indianapolis
Louisiana
- Jennifer Feng — New Orleans
Missouri
- Robert Naismith — St Louis
Ohio
- Aaron Boster — Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2023-09-22 |
| Est. Completion | 2027-05-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05816122
The ClinicalTrials.gov registry entry for NCT05816122 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ad scientiam, which has 35 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention — of which MSCopilot® Detect mobile application is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05816122 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Other, California, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05816122 about?
NCT05816122 is a clinical study titled "MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect". The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS). The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Wor...
What is the current status of trial NCT05816122?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 336 participants. The study started on 2023-09-22. Estimated completion is 2027-05-31.
What conditions does trial NCT05816122 study?
This clinical trial studies the following conditions: Multiple Sclerosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05816122?
The interventions under investigation include: MSCopilot® Detect mobile application (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05816122?
This trial is sponsored by Ad scientiam, which has 35 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05816122 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.